MWN109 1
Sponsors
Shanghai Minwei Biotechnology Co., Ltd
Conditions
Overweight , ObesityType 2 Diabetes Mellitus (T2DM)
Phase 1
Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight or Obesity
CompletedNCT07791654
Start: 2025-08-23End: 2026-03-21Updated: 2026-08-28
Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight
Active, not recruitingNCT07791537
Start: 2025-12-26End: 2026-11-01Updated: 2026-08-28
Phase 2 Study of MWN109 Tablet in Participants With Overweight or Obesity
CompletedNCT07791524
Start: 2026-01-05End: 2026-07-09Updated: 2026-08-28
Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus
RecruitingNCT07801820
Start: 2026-06-23End: 2027-03-01Target: 240Updated: 2026-09-09
Phase 2 Study of MWN109 Tablet for Weight-Loss Maintenance in Participants With Overweight or Obesity
Active, not recruitingNCT07804797
Start: 2026-03-02End: 2026-09-01Updated: 2026-09-04